Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07268638 · ClinicalTrials.gov registry record · Phase 2
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2 study of Focal Segmental Glomerulosclerosis, sponsored by Akebia Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT07268638 is a Phase 2 study of Focal Segmental Glomerulosclerosis that is actively recruiting participants, run by Akebia Therapeutics. The registered enrollment target is 60 participants, below the 234-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (74% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT07268638, a Phase 2 study of Focal Segmental Glomerulosclerosis, is actively recruiting participants, sponsored by Akebia Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Praliciguat
Study Locations (8)
Florida
- Investigator Site #6 - Coral Springs
- Investigator Site #7 - Miami
- Investigator Site #8 - Orlando
California
- Investigator Site #2 - Chula Vista
Georgia
- Investigator Site # 1 - Lawrenceville
Illinois
- Investigator Site #3 - Chicago
Tennessee
- Investigator Site #4 - Chattanooga
Texas
- Investigator Site #5 - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07268638
The ClinicalTrials.gov registry entry for NCT07268638 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 234-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (74% lower). The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07268638 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07268638 about?
NCT07268638 is a clinical study titled "A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)". This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial ...
What is the current status of trial NCT07268638?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-12-03. Estimated completion is 2028-01.
What conditions does trial NCT07268638 study?
This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis.
What interventions are being tested in trial NCT07268638?
The interventions under investigation include: Placebo (OTHER), Praliciguat (DRUG).
Who is sponsoring clinical trial NCT07268638?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07268638 being conducted?
This trial has 8 study locations across California, Florida, Georgia, Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Segmental Glomerulosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
RECRUITING · Phase 2
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
-
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.